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Abstract
MicroRNA-224 (miR-224) is frequently over-expressed in liver and colorectal cancers. We and others have previously
described the role of miR-224 over-expression in cell proliferation in vitro but we have yet to identify the relevant miR-224
direct target. In this study, we further demonstrated that miR-224 up-regulation promotes cell proliferation using both
in vitro assays and in vivo tumor growth models. We systematically screened for high confidence miR-224 targets by
overlapping in silico predicted targets from multiple algorithms and significantly down-regulated genes in miR-224-
expressing cells from whole genome expression microarrays. A total of 72 high confidence miR-224 targets were identified
and found to be enriched in various cancer-related processes. SMAD family member 4 (SMAD4) is experimentally validated
as the direct cellular target through which miR-224 promotes cell proliferation. The clinical relevance of our experimental
observations was supported by a statistically significant inverse correlation between miR-224 and SMAD4 transcript
expression in tumor versus paired adjacent non-tumorous tissues from HCC patients (p,0.001, r =20.45, R2 = 0.122).
Furthermore, miR-224 up-regulation and SMAD4 down-regulation is significantly associated with poorer patient survival
(p,0.05). In summary, miR-224/SMAD4 pathway is a clinically relevant pathway to provide new insights in understanding
HCC. (191 words).
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Introduction
Aberrant microRNA expression features significantly in many
cancers [1]. Many of these deregulated miRNAs are found to
regulate crucial cellular targets such as Phosphatase and Tensin
Homolog [2] and Signal Transducer and Activator of Transcrip-
tion 3 [3]. miR-224 is one of the most commonly up-regulated
miRNAs in HCC [4] and more recently also found to be over-
expressed in other cancers such as colorectal cancer[5–7], cervical
cancer [8] glioma [9] and breast cancer cells [10],suggesting
elevated miR-224 expression may play a role in the general
process of carcinogenesis.
The potential oncogenic property of miR-224 was demonstrat-
ed by various groups using in vitro cell line models to affect crucial
cellular processes such as apoptosis [11], cell proliferation [11–13],
cell migration and invasion [12–14]. We have previously reported
apoptosis inhibitor 5 as a miR-224 direct target in the liver [11]
while other groups have reported a handful of other miR-224
targets such as Smad family member 4 [13], Raf kinase inhibitor
protein [10] and Type 1 iodothyronine deiodinase [15] in various
other cell systems. However, a systematic examination of the direct
cellular targets of miR-224 is important to understand its role in
cancer. Furthermore, the in vivo function and the clinical
significance of miR-224 over-expression in cancers such as HCC
remain unclear.
In this study, we further characterized the role of miR-224 in
promoting cell proliferation using both in vitro cell-based assays
in vivo tumor explants in nude mice. We systematically screened for
high confidence miR-224 putative targets by integrating in silico
prediction and whole genome expression microarray data. SMAD
family member 4 (SMAD4) was functionally validated as the
clinically relevant cellular target through which miR-224 promotes
cell proliferation. MiR-224 over-expression and SMAD4 down-
regulation significantly correlates with a poorer overall survival in
HCC patients.
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Materials and Methods
Cell Lines, Mice and Patient Samples
Human colorectal HCT116 cells were cultured in modified
McCoy’s 5A media (M4892,Sigma) supplemented with 10% fetal
calf serum (04-001-1A/A, Bioindustries). Human hepatoma
HepG2 cells were cultured in Dulbecco’s Modified Eagle Medium
supplemented with 10% fetal calf serum. The cells were incubated
at 37uC in a humidified atmosphere with 5% CO2. BALB/c nude
mice were purchased from Biological Research Centre, Singapore.
This study received ethical approval from National Cancer Centre
Singapore (NCCS) Institutional Animal Care and Use Committee
(IACUC: 2009/SHS/504A). HCC tumor and paired adjacent
non-tumorous tissues from 100 hepatocellular carcinoma patients
were obtained from the NCCS Tissue Repository with prior
approval from the SingHealth Centralized IRB (SingHealth CIRB
No: 2008/440/B).
Whole Genome Expression Microarray
HCT116 cells were transfected with either 50 nM of Control
Oligos or miR-224 precursors and harvested 24 hours post
transduction. Total RNAs were extracted using mirVanaTM
microRNA Isolation Kit (AM1560, Ambion) and processed for
Affymetrix Genechip (Affymetrix) hybridizations using U133A
Genechips according to the instructions of the respective
manufacturer. The hybridization signal on the chip was scanned
and processed by GeneSuite software (Affymetrix). The micro-
array data can be retrieved from GEO database (GSE36020).
In Silico Prediction of miR-224 Targets and Functional
Annotation
miR-224 targets were predicted in silico using the miRecords
[16]. Putative miR-224 targets were defined as those predicted by
at least three independent algorithms. Gene list were mapped to
gene ontology (GO) terms using DAVID [17,18] and IDconverter
[19].
RT-qPCR and Western Blot Analysis
As previously described [3,11], microRNA expression was
determined using individual Taqman microRNA assay and
transcript expression of target genes was measured with SYBR
RT-qPCR (204143, Qiagen), normalized against endogenous
control RNU48 and b-actin respectively. Protein expression was
measured with Western blots and normalized against b-actin.
miRNA assay ID, primer sequences and antibody ID are listed in
Table 1.
39UTR Reporter Construct and Reporter Gene Assay
The 1313 base pairs (bps) wild type SMAD4 39UTR
(pSMAD4UTR-WT) and the miR-224 binding site mutant
39UTR (pSMAD4UTR-MUT) were amplified from human
placenta tissue and cloned downstream a b-galactosidase reporter
gene (Fig. S1 in File S1). 39UTR reporter assays were performed
as previously described [3,11].
Stable Cell Line Generation
The pLemiR (miR-224) construct was purchased from Open
Biosystems and the miR-224 insert was removed to serve as the
control contruct. Both the pLemiR(miR-224) and the pLemiR(-
control) constructs were then transfected into HCT116 cells to
generate stable clones under selection media containing 1 ug/ml
of puromycin for 2 weeks. Clonal cells, which showed resistance to
puromycin treatment and expressed turbo red fluorescence protein
(tRFP), were further expanded and tested for miR-224 expression
using RT-qPCR (Fig. S2 in File S1). Positive clones were grown in
selection media for another 4 weeks to confirm stable expression.
Two independent control clones (Clone 1 & 2) and two
independent miR-224 expressing clones (Clone A & B) were used
for subsequent functional assays.
In vitro and in vivo Functional Assays
Cell proliferation was measured using the BrdU Cell Prolifer-
ation Kit (Calbiochem) accordingly to manufacturer’s instructions.
Soft-agar colony forming assay were performed using two stable
clones of miR-224 over-expressing cells and two stable clones of
controls as previously described [20]. In vivo tumor growth was
performed by subcutaneously injecting 56106 cells stably express-
ing miR-224 (clone A) or control (clone 1) into the left or right
flanks of four BALB/C nude mice, respectively. The experiment
was repeated using miR-224 expressing clone B paired with
control clone 2 in three nude mice. Tumor size were measured on
day 10, 20 and 26 post injection and tumor weight were measured
on day 26 when the mice were sacrificed.
Statistical Analysis
Analysis of Variance was used to compare sample means from
three or more groups. Unpaired two-tailed t test was further
performed to analyze the significance of differences between
sample means between two groups from at least three independent
experiments. Pearson correlation was used to analyze the
relationship between the expression of miR-224 and SMAD4 in
HCC patient samples. Kaplan-Meier survival analysis was used to
analyze association of miR-224 & SMAD4 status and patient
survival. Statistically significant tests were identified with p value
less than 0.05.
Results
miR-224 Promotes Cell Proliferation in vitro and in vivo
miR-224 is found to be frequently over-expressed in hepatocel-
lular carcinoma [4,11] and colorectal cancer [5–7]. To understand
the functional relevance of miR-224 over-expression in cancer, we
initially over-express miR-224 in the human colon cancer cell line,
HCT116, which exhibit low endogenous miR-224 expression (Fig.
Table 1. Small oligos, Taqman assays, primer sequences,
antibodies.
Genes Items Sequence/Catalog ID
hsa-miR-224 Control Oligos Ambion, AM17110
Precursor Ambion, PM12571
Inhibitor Ambion, AM12571
Taqman Assay ABI, 4373187
hsa-let-7d Taqman Assay ABI, 4373166
RNU48 Taqman Assay ABI, 4373383
SMAD4 Primer F: 59-AGGATCAGTAGGTGGAATAG-39
R: 59-TCTAAAGGTTGTGGGTCTGC-39
Antibody Santa cruz, SC-56479
siRNA Sigma, SASI_Hs01_00207793
Beta-actin Primer F: 59-ATGTTTGAGACCTTCAACACC-39
R: 59-AGGTAGTCAGTCAGGTCCCGGCC-39
Antibody Santa cruz, SC-1646
doi:10.1371/journal.pone.0068744.t001
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S3 in File S1). As shown in Figure 1A, ,30% increase in cell
proliferation (p,0.05, right panel, grey bar) was observed in cells
over-expressing miR-224 (p,0.001, left panel, grey bar) compared
to the Control Oligos transfected cells (white bar). Significantly,
when miR-224 inhibitor and precursor were co-introduced into
cells, the miR-224 over-expression was significantly inhibited
(p,0.001, left panel, black bar) and cell proliferation was restored
to a level similar to control cells (p = 0.58, right panel, black bar).
These findings were then validated in the human hepatoma cell
line HepG2 which exhibits moderate level of endogenous miR-224
levels (Fig. S3 in File S1). Similar to the observation in HCT116
cells, over-expression of miR-224 in HepG2 cells lead to a ,35%
increase in cell proliferation (p,0.01, Fig. S4 in File S1, rightmost
panel, grey bar) while inhibition of endogenous miR-224 resulted
in ,20% decrease in cell proliferation (p,0.01, Fig. S4 in File S1,
rightmost panel, black bar). The expression of unrelated let-7d
remained unchanged, demonstrating the specificity of these small
oligos in perturbing endogenous miR-224 level. Furthermore,
triplicate experiments from two independent clonal cells stably
expressing miR-224 (Clone A & B, p,0.001, Fig. 1B inset) formed
, five-fold more colonies on soft-agar compared to triplicate
experiments from two independent control clones (Clone 1 & 2,
p,0.01, Fig. 1B). Taken together, miR-224 over-expression
promotes in vitro cell proliferation under both normal growth
conditions and in soft-agar.
We proceeded to confirm our in vitro observations using an
in vivo xenograft model in nude mice. Both miR-224 expressing
(Clone A & B) and control stable cells (Clone 1 & 2) were able to
form tumors 10 days after subcutaneous injection. Tumors from
cells stably expressing miR-224 grew significantly faster than stable
control cells (p,0.05, Fig. 1C). Furthermore, on Day 26, tumors
harvested from miR-224-expressing stable cells were significantly
heavier than the tumors from the control stable cells (p,0.05,
Fig. 1D). Hence, over-expression of miR-224 not only promotes
cell proliferation in vitro and but also tumor growth in vivo.
Figure 1. miR-224 promotes cell proliferation in vitro and in vivo. (A) Relative transcript expression of miR-224 (left panel) and non-specific
let-7d expression (middle panel) measured using RT-qPCR and normalized against RNU48. Right panel shows the corresponding changes in cell
proliferation measured with BrdU cell proliferation assay in cells transfected with either 50 nM of Control Oligos, miR-224 precursor or miR-224
precursor+inhibitor. (B) Colony formation from two stable clones of control (1 & 2) and two stable clones miR-224 expressing cells (A & B) grown on
soft agar. Inset shows miR-224 expression and representative colony formation from the stable clones. Data in (A) and (B) were presented as
Mean6SE from at least three independent experiments. (C) In vivo tumor growth from control or miR-224 expressing stable clones from (B)
subcutaneously inoculated into BALB\c nude mice and plotted as tumor size versus time post subcutaneous injection. (D) Left: Average weight of
tumors harvested from 4 mice each from clones 1 (control) and A (miR-224) or 3 mice each from clones 2 (control) and B (miR-224) at Day 26 post
injection. Inset shows miR-224 expression in tumors from control or miR-224 expressing cells. Right: Photograph of representative mice inoculated
with control or miR-224 expressing cells in the left and right dorsal area respectively. Data shown in (C) and (D) were presented as Mean6SD from
four/three sacrificed nude mice per group respectively. * denotes p,0.05, ** denotes p,0.01 and *** denotes p,0.001.
doi:10.1371/journal.pone.0068744.g001
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miR-224 Potentially Targets Multiple Crucial Cellular
Processes
As miRNAs affect cellular processes by regulating specific set of
gene targets, whole genome expression microarray was employed
to determine the profile of differentially expressed genes between
miR-224 over-expressing cells and the control cells in three
independent experiments. Greater than 3-fold more genes were
found to be significantly down-regulated (161, |FC| .1.5,
p,0.05) than up-regulated (47, |FC|,1.5, p,0.05), consistent
with miRNAs being negative regulators of gene expression (Fig. 2A
& Fig. 2B). Of the 161 genes that were down-regulated in miR-224
expressing cells, 72 (,44.7%) were also predicted to be miR-224
direct cellular targets by at least three independent algorithms
while only 7 of 47 (14.9%) up-regulated genes were predicted as
Figure 2. Putative miR-224 targets were significantly down-regulated in miR-224 expressing cells. (A) Volcano plot analysis of whole
genome expression microarray data between cells transfected with miR-224 precursor and Control Oligos from three independent experiments.
Differentially expressed genes that were both biologically and statistically significant were indicated in the two upper-lateral quadrant with absolute
fold change .1.5 and p-value ,0.05. Green spots indicated significantly down-regulated genes while red spots indicated significantly up-regulated
genes in miR-224 expressing cells versus control cells. (B) Stacked barchart showing a significant enrichment of putative miR-224 targets in the
significantly down-regulated genes in miR-224 expressing cells versus control cells. White box represents putative miR-224 targets predicted by at
least three different algorithms while grey box represents the non-miR-224 target genes. Proportions of the predicted and non-predicted targets
were indicated as percentages on the right of the intended box. P value is calculated from x2 test.
doi:10.1371/journal.pone.0068744.g002
Table 2. Gene ontology mapping of putative miR-224 targets which were significantly down-regulated in miR-224 expressing
cells.
GO Term GO ID Genes Annotated to the GO term
Regulation of transcription DNA-
dependent
GO:0006355 NFATC2IP, CDC42, SMAD4, ZNF395, C10ORF26, ZFP90, ZBTB43, TMF1, TFB1M, GCOM1
Metabolic process GO:0008152 INSIG1, RDH10, SGPL1, HSDL1, TPD52, PFKFB3, PPAT
Apoptosis GO:0006915 UBE4B, API5, SH3KBP1, SGPL1, RFFL
Signal transduction GO:0007165 F2RL1, GRB10, CDC42BPA, RALA, GCC1
Protein phosphorylation GO:0006468 CDC42BPA, SGK3, NUAK1
Proteolysis GO:0006508 TPD52, ZFP90, ADAM17
Ubiquitin cycle GO:0006512 UBE2D3, USP3, RFFL
Transport GO:0006810 SLC37A4, TMED10, INSIG1
Intracellular protein transport GO:0006886 FPNA6, RALA, RFFL
Cell-cell signalling GO:0007267 SH3KBP1, ADAM17, GRB10
Protein transport GO:0015031 TMED10, RALA, LIN7C
Protein ubiquitination GO:0016567 FBXL5, SUMF1, UBE4B
Anti-apoptosis GO:0006916 API5, SGK3
Cell proliferation GO:0008283 INSIG1
Negative regulation of cell proliferation GO:0008285 SMAD4
doi:10.1371/journal.pone.0068744.t002
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miR-224 targets. These 72 significantly down-regulated genes
which are also predicted as miR-224 targets by multiple
algorithms are termed as high confidence miR-224 targets (miR-
224 hc-targets) and further analyzed to elucidate the processes
they affect. Apoptosis inhibitor 5 (API5), the only previously
validated target of miR-224 in HCC [16], was found to be also
amongst the 72 miR-224 hc-targets reaffirming the feasibility of
this approach. As evident in Table 2, miR-224 hc-targets are
enriched in cancer-related GO processes such as regulation of
transcription, metabolic processes, apoptosis and signal transduc-
tion, suggesting that miR-224 over-expression can potentially
affect multiple cellular processes.
SMAD4 is a Direct Cellular Target of miR-224
Amongst the 72 miR-224 hc-targets, SMAD4 is the only
negative regulator of cell proliferation (Table 2), playing a role
as an essential mediator of the transforming growth factor-beta
(TGF-b) pathway, which acts as a potent inhibitor of cell
proliferation [21]. We thus hypothesize that miR-224 can promote
cell proliferation via targeting SMAD4.
To experimentally validate SMAD4 as a miR-224 specific
target, the wild type SMAD4 39UTR (39 untranslated region) as
well as a mutant 39UTR in which the two putative miR-224
binding sites were mutated, were cloned downstream a b-
galactosidase (b-gal) reporter gene (Fig. 3A, left panel). Introduc-
tion of miR-224 precursors into cells containing wild-type SMAD4
39UTR reporter construct resulted in significantly lower (p,0.01)
b-gal activity compared to cells carrying the mutant SMAD4
39UTR reporter construct in which the miR-224 binding sites are
mutated (Fig. 3A, right panel). No significant difference was
observed between cells carrying wild-type or mutant SMAD4
39UTR reporter construct when Control Oligos were introduced.
These data suggest that miR-224 specifically interacted with its
Figure 3. SMAD4 is a direct miR-224 target. (A) Left: Schematic diagram of the 39UTR reporter constructs utilized to validate that the miR-224
targets the 39UTR region of SMAD4, with the putative miR-224 binding sites and the mutated form highlighted in the box below. Right: Inhibitory
effect of miR-224 on SMAD4 39UTR examined through normalized b-galactosidase activity in cells co-transfected with Control oligos or miR-224
precursor and wild type SMAD4 39UTR (Black bar) or mutant SMAD4 39UTR reporter construct (White bar). (B) Relative SMAD4 transcript expression
measured with RT-qPCR and normalized against b-actin (left panel) and SMAD4 protein expression measured by Western blotting in cells transfected
with 50 nM of Control Oligos, miR-224 precursor or miR-224 precursor+inhibitor. (C) Relative SMAD4 transcript expression measured in the in vivo
tumors arose from control (1 & 2) and miR-224 (A & B) stable clones expressing miR-224 (from Fig. 1D). (D) Relative fold change of miR-224 (Leftmost
panel) and SMAD4 transcript expression (middle panel) and corresponding changes in cell proliferation measured with BrdU cell proliferation assay
(rightmost panel) in cells transfected with either 50 nM of Control Oligos (white bar), miR-224 precursor (grey bar) or siRNA against SMAD4 (black
bar). Inset shows the inhibition of SMAD4 protein by miR-224 precursor and siRNA against SMAD4. Data presented as Mean 6 SE from three
independent experiments. * denotes p,0.05, ** denotes p,0.01 and *** denotes p,0.001.
doi:10.1371/journal.pone.0068744.g003
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putative binding sites along SMAD4 39UTR to negatively regulate
b-gal reporter gene activity.
The ability of miR-224 to modulate endogenous SMAD4
expression was then evaluated. Both SMAD4 transcript and
protein expression were significantly reduced by ,50% (p,0.05)
in HCT116 cells transfected with miR-224 precursors and their
expression can be partially reverted to normal by the co-
transfection with both miR-224 precursor and inhibitor (Fig. 3B).
No significant difference between miR-224-expressing and control
cells was observed in the expression of transforming growth factor
alpha (TGFA), beta (TGFB1 and TGFB2) and their receptors
(TGFBR2 and TGFBR3), (Fig. S5 in File S1). Similarly, compared
to control human hepatoma HepG2 cells, SMAD4 transcript
expression was significantly reduced by ,40% (p,0.05) in cells
where miR-224 precursor was introduced and significantly
increased by ,60% (p,0.001) in cells where miR-224 inhibitor
was introduced (Fig. S4 in File S1). Inhibition of SMAD4
expression was observed in tumors generated by miR-224
expressing stable clones (Clone A & B) compared to the control
clones (Clone 1 & 2) (Fig. 3C). Taken together, our data
demonstrates that SMAD4 is a direct miR-224 target.
To ascertain that SMAD4 is indeed a target through which
miR-224 affects cell proliferation, SMAD4 expression was
inhibited using siRNA that specifically targets SMAD4. As shown
in Figure 3D, inhibition of SMAD4 expression in cells increased
cell proliferation by ,30% (p,0.05, black bar) which was
phenotypically similar to the effect of overexpression of miR-224
by miR-224 precursors (p,0.05, grey bar). Taken together, these
data strongly suggest SMAD4 as a miR-224 specific target through
which miR-224 promotes cell proliferation.
miR-224-SMAD4 is a Clinically Relevant Pathway in HCC
We proceeded to evaluate the clinical relevance of our
experimental observation by examining the expression of miR-
224 and SMAD4 in the tumor and paired adjacent non-tumorous
tissues from 100 HCC patients. A significant inverse correlation
(p,0.001, r =20.45, R2= 0.122) was observed between the
expression of miR-224 and SMAD4 in these HCC samples
(Fig. 4A), suggesting SMAD4 as a clinically relevant miR-224
target in HCC. Although either miR-224 up-regulation or
SMAD4 down-regulation alone did not show any significant
association with overall patient survival (Fig. S6 in File S1), HCC
patients with tumors which exhibits more than 2 fold up-regulated
miR-224 and more than 1.5 fold down-regulated SMAD4
expression compared to the paired adjacent non-tumorous tissues
were found to be significantly associated with poorer overall
survival (p,0.05, Fig. 4B). Collectively, these data suggest that
deregulation of miR-224 expression with subsequent deregulation
of SMAD4 expression may serve as a prognostic biomarker
predicting the patients’ survival outlook.
Discussion
MicroRNA deregulation features significantly in tumorigenesis
[1] and miR-224 is frequently observed to be over-expressed in a
number of cancers. Recent evidence has linked miR-224 up-
regulation in cancer with epigenetic reprogramming [22] and
inflammation [23]. We and others have previously demonstrated
that miR-224 up-regulation promotes cell proliferation [11–13]
in vitro. Here we have further confirmed that high miR-224
expression also promotes tumor growth in vivo. To identify the
cellular target through which miR-224 promotes cell proliferation
we systematically screened for miR-224 putative targets by
integrating multiple in silico miRNA-target gene prediction
algorithms with experimental whole genome expression profiling
of cells expressing miR-224. We identified a total of 72 high
confidence miR-224 targets (hctargets), which are in silico predicted
miR-224 targets with significantly reduced expression in miR-224
expressing cells (Fig. 2). Amongst these miR-224 hctargets, is
Figure 4. Up-regulation of miR-224 and down-regulation of SMAD4 expression is associated with poorer survival of HCC patients.
(A) Scatter plots showing the statistically significant correlation in the relative transcript expression of miR-224 and SMAD4 (p,0.001) in the tumor
versus paired adjacent non-tumor tissues from 100 HCC patients. Each spot represents data from one HCC patient presented in the Log2 scale and
the linear regression line is depicted at the solid line. (B) Kaplan-Meier survival curve for 46 HCC patients classified based on whether HCC tumor
showed miR-224 up-regulation (more than 2 fold) and SMAD4 down-regulation (more than 1.5 fold), compared to the paired adjacent non-tumor
samples. Up-regulation of miR-224 and down-regulation of SMAD4 expression is significantly associated with poorer patient survival (log rank,
p = 0.019).
doi:10.1371/journal.pone.0068744.g004
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API5, which was previously experimentally validated to be a
specific target of miR-224 [11] providing confidence of our
approach of identifying ‘genuine’ gene targets of miR-224. These
miR-224 hctargets were predicted to potentially affect multiple
cellular processes such as transcription, metabolism, cell prolifer-
ation and apoptosis, all of which play roles in tumorigenesis.
Notably, consistent with a recent report by Yao, et al who
demonstrated that miR-224 is regulated by TGF-b/SMAD
pathway and targets SMAD4 in mouse granulosa cells [13], our
study also showed that in the human HCT116 cells, miR-224
indeed directly targets SMAD4, the central mediator of TGF-b
pathway, to promote cell proliferation. Transforming growth
factor beta (TGF-b) is a central regulator in chronic liver diseases
that ranges from inflammation to cancer. Many studies have
described a bipartite role of TGF-b with tumor suppressor
functions that inhibits hepatocyte proliferation at early stages of
liver cancer and oncogenic function that promotes invasion and
metastasis at late stage of tumor progression [24]. Interestingly,
miR-224 does not directly affect the expression of TGFa, TGFb1
and TGFb2 or their receptors (TGFbR2 and TGFbR3). miR-224
up-regulation was shown to be an very early event that precedes
tumor transformation [22]. Our data suggests that in the early
events of tumorigenesis, miR-224 up-regulation may suppress the
antiproliferative function of TGF-b by down-regulating SMAD4
and attenuating the transcriptional response of TGF-b signalling
transduction [25]. This is supported by that fact that SMAD4
knockout mice developed tumors throughout the gastrointestinal
tract [26] and inactivation of SMAD4 has been shown to markedly
attenuate the TGF-b-mediated antiproliferative response [27].
Although homozygous deletions or intragenic mutations account
for up to 60% of the SMAD4 inactivation in pancreatic and
colorectal carcinoma, no homozygous deletion and only 6% of
intragenic mutations of SMAD4 were detected in HCC [25]. In
this study, we provided evidence that SMAD4 could also be
regulated by the aberrant expression of miR-224. Our observa-
tions, together with Yao et al. who demonstrated that miR-224 is
regulated by TGF-b/SMAD pathway and targets SMAD4 in
mouse granulosa cells [13] suggest the physiological role of miR-
224 in the TGF-b signaling negative feedback loop. Curiously, at
late stages of HCC, both miR-224 and TGF-b are shown to be
over-expressed in HCC, promoting invasion and metastasis
[12,21]. However, it remains to be evaluated whether the
underlying mechanisms are common or independent.
In summary, this study demonstrated that miR-224 up-
regulation promotes cell proliferation in vitro and in vivo. Notably,
deregulation of miR-224 together with its clinically relevant direct
target gene, SMAD4 was found to be significantly associated with
HCC patient survival status. Hence, miR-224-SMAD4 may
represent a novel pathway for prognostic and therapeutic
intervention.
Supporting Information
File S1 Figure S1, Strategy, primers and product of
mutagenesis of SMAD4 39UTR. (A) Strategy for the
generation of mutations at the miR-224 binding site of SMAD4
39UTR. (B) Primers used for the generation of mutations at the
miR-224 binding site of SMAD4 39UTR. Figure S2, Strategy
to generate stable clonal cells expressing miR-224. (A)
Vector map of pLemiR construct in which tRFP, microRNA and
puromycin resistance gene will be transcribed in a single long
transcript. Positive clones will be resistant for puromycin and
positive for RFP and the microRNA of interest. (B) A
representative clone during selection. Figure S3, Endogenous
miR-224 expression in various cancer cell lines mea-
sured using Taqman RT-qPCR and normalized against
RNU48 as endogenous control. Figure S4, Relative
transcript expression of miR-224, non-specific let-7d
and SMAD4 measured using RT-qPCR and normalized
against RNU48 or beta-actin. Right panel shows the
corresponding changes in cell proliferation measured with BrdU
cell proliferation assay in human hepatoma cell line HepG2 cells
transfected with either 50 nM of Control Oligos, miR-224
precursor or miR-224 inhibitor. Figure S5, Relative transcript
expression of transforming growth factor alpha (TGFA), beta
(TGFB1 & TGFB2) and relevant receptors (TGFBR2 & TGFBR3)
in HCT116 cells transfected with miR-224 precursors versus that
with control oligos, as measured through cDNA microarrays.
Figure S6, Kaplan-Meier survival curve for 46 HCC
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